Misplaced Pages

Chronic spontaneous urticaria

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Chronic idiopathic urticaria) Medical condition
Chronic spontaneous urticaria
Other namesChronic idiopathic urticaria, CIU, and CSU.
Typical presentation of chronic spontaneous urticaria.
SpecialtyDermatology
SymptomsUrticaria, angioedema, headache, fatigue, joint pain or swelling, gastrointestinal symptoms flushing, wheezing, and palpitations.
Usual onsettypically 30s-50s
DurationEpisodic.
CausesNSAIDs, heat, tight clothing or straps, stress, variations in diet, and alcohol.
Risk factorsAllergic diseases, autoimmune conditions, and thyroid disorders.
Diagnostic methodClinical findings, complete blood count with differential, CRP or ESR, and skin biopsy.
Differential diagnosisUrticarial vasculitis, lupus, cryoglobulinemia, Schnitzler syndrome, mast cell disorders, polymorphic eruption of pregnancy, hypereosinophilic syndrome, and Cryopyrin-associated periodic syndromes.
TreatmentAvoidance of exacerbating factors, and antihistamines.
MedicationCetirizine, Levocetirizine, Fexofenadine, Loratadine, and Desloratadine.
PrognosisSpontaneous remission in 30-50% of cases.
Frequency1% of the general population in the United States.

Chronic spontaneous urticaria (CSU) also known as Chronic idiopathic urticaria (CIU) is defined by the presence of wheals, angioedema, or both for more than six weeks. The most common symptoms of chronic spontaneous urticaria are angioedema and hives that are accompanied by itchiness.

Chronic spontaneous urticaria, despite its cause being unknown, is linked to a higher prevalence of autoimmune diseases, and is often worsened by triggers like stress, infections, certain foods, or nonsteroidal anti-inflammatory drugs. The hives and angioedema seen in CSU is thought to be linked to the degranulation of skin mast cells. Mast cells release proteases, histamine, cytokines, and arachidonic acid metabolites, causing swelling, redness, and itching.

The standard workup for CSU differs in different parts of the world. However, most doctors agree on the importance of having a detailed history. The main goal is to identify any urticaria-inducing factors because eliminating them is the most straightforward course of treatment. Basic laboratory tests, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and possibly a complete blood count (CBC) with differential, are critical for detecting signs of systemic inflammation and ruling out autoinflammatory conditions as well as urticarial vasculitis with systemic involvement.

For the treatment of chronic spontaneous urticaria, a two-pronged strategy has been proposed. The underlying cause(s) and/or eliciting trigger(s) must first be identified and eliminated. The second approach is pharmacotherapy, which aims to alleviate symptoms. A therapeutic approach should be implemented in three steps, according to current guidelines: (1) taking a second-generation antihistamine once daily; (2) increasing the second-generation antihistamine's daily dose up to four times; and (3) pursuing off-label therapy with cyclosporine A or montelukast or add-on therapy with omalizumab, which is an approved treatment option for CSU.

Signs and symptoms

Angioedema, excruciatingly itchy recurrent wheals, or both can be signs of chronic spontaneous urticaria. Between 40 and 50 percent of CSU patients experience angioedema. However, angioedema is the main symptom reported by about 10% of patients.

Usually, urticarial lesions or hives are elevated, erythematous plaques with a defined perimeter. If a patient is taking antihistamines, these lesions may appear flattened and take on a range of sizes. It can affect any part of the body, including parts where clothing might press against the skin. Lesions typically do not last more than 24 hours. The degree of pruritus can interfere with everyday activities and sleep.

Angioedema is characterized by sporadic, asymmetrical submucosal or subcutaneous edema. It is more common to experience paresthesia, such as tingling or numbness, than the pruritus associated with urticaria. Often affected body parts are the lips, eyes, cheeks, and limbs. Urticaria and angioedema typically coexist, but in a small percentage of cases, angioedema may be the only symptom.

Causes

While the cause of chronic spontaneous urticaria is unknown many individuals with chronic urticaria have been found to have a higher prevalence of various autoimmune diseases. Many patients with chronic spontaneous urticaria report that certain triggers, like stress, infections, certain foods, or nonsteroidal anti-inflammatory drug consumption, cause their disease to worsen.

Risk factors

There is evidence that individuals with chronic urticaria are more likely to have a variety of autoimmune diseases. Researchers found that patients with systemic lupus erythematosus, rheumatoid arthritis, thyroid issues, celiac disease, Sjögren syndrome, and type 1 diabetes had higher rates of these conditions than those with chronic urticaria in a study involving a database of 13,000 patients compared to 10,000 control subjects.

Triggers

The majority of patients with chronic spontaneous urticaria frequently linked multiple triggers to flare-ups. However, the suspected trigger does not always result in symptoms, so patients frequently subject themselves to needless limitations and lifestyle modifications.

In one study, the most common type of idiopathic urticaria among CSU patients was symptomatic dermographism. The second most common physical trigger that was reported was pressure. The third most commonly reported trigger was cold.

The majority of guidelines discourage food as the cause of chronic urticaria; nonetheless, patients frequently believe that certain foods aggravate their condition or are the cause of it. Between 13 and 80% of people self-report that food triggers their CSU episodes.

A contributing factor to the exacerbation of chronic spontaneous urticaria in certain patients may be stress. On the other hand, urticaria is most likely one of the main sources of stress.

Mechanism

Two mast cells in bone marrow at 1000x magnification after Wright staining.

The degranulation of skin mast cells in CSU appears to be involved in wheals and angioedema. These cells release proteases, histamine, and cytokines along with platelet-activating factors and other metabolites of arachidonic acid. These mediators cause swelling, redness, and itching by stimulating sensory nerve endings, increasing vascular permeability, and inducing vasodilatation. Edema, mast cell degranulation, and a perivascular infiltrate of cells, including CD4ξ lymphocytes, monocytes, neutrophils, eosinophils, and basophils, are the hallmarks of a lesion site, also known as a wheal. This infiltrate bears resemblance to the infiltrate observed in the allergen late-phase reaction. T-cell expression of IL-4, IL-5, and IFN-g is evident in the lesion cytokine profile, indicating a mixed TH1/TH2 response. The dermis of lesion skin contains epithelial-derived cytokines that support the TH2 profile, such as IL-33, IL-25, and thymic stromal lymphopoietin, as well as the vasoactive agents calcitonin gene-related peptide and vascular endothelial growth factor. These factors were not present in the skin that is not affected. The pathophysiology of chronic urticaria is the subject of several theories, none of which has been proven beyond a reasonable doubt. Research has looked at the validity of serologic testing to establish an autoimmune basis for disease as well as the autoimmune theory of illness. Other theories include additional serologic factors, abnormalities of tissue mast cells, and basophils.

Diagnosis

Chronic spontaneous urticaria is defined by the presence of wheals, angioedema, or both for more than six weeks.

In various areas of the world, the standard workup is different. A very comprehensive history is something that is universally agreed upon. The main goal is to identify any urticaria-inducing factors, as the most straightforward course of treatment is to eliminate them, including physical provocation factors, food allergies, etc. Provocations such as double-blinded, placebo-controlled food provocation, pressure, heat, cold, and others should be used if an eliciting factor is suspected in order to confirm if it is an eliciting factor. Because chronic as well as recurrent infections are known to cause urticaria, only differential blood counts and CRP or ESR are advised if no symptom-inducing factor can be found.

Urticarial autoinflammatory diseases and urticarial vasculitis (UV) are uncommon but should be taken into consideration in patients who experience recurrent wheals. Doctors should ask about the duration as well as resolution of each wheal as well as the presence of any other signs and symptoms, such as fever episodes or musculoskeletal pain, in addition to itchy wheals or angioedema, in order to rule out both conditions. Extended periods of time exceeding twenty-four hours and a gradual resolution of individual wheals indicate UV exposure; further indications of systemic inflammation may indicate autoinflammatory disease as well as other autoimmune disorders. A skin biopsy should be part of the diagnostic process if UV as well as an autoinflammatory disease is suspected. This is so that neutrophilic infiltrates or vascular destruction can be checked for. It could be challenging to differentiate UV from CSU because there are currently no established standardized histopathologic criteria for UV. Basic laboratory tests, which include inflammatory markers C-reactive protein (CRP) as well as erythrocyte sedimentation rate (ESR) and possibly complete blood count (CBC) with differential, are crucial to detect signs of systemic inflammation and rule out autoinflammatory conditions as well as UV with systemic involvement. However, these results can also be influenced by other comorbidities and can be seen in CSU.

Patients with recurrent wheals need to have a number of other conditions taken into consideration. Certain conditions, like hypereosinophilic syndromes and Wells syndrome, are uncommon. The primary skin lesions in these patients vary, ranging from permanent maculopapular lesions to long-lasting plaque-like lesions, even though they may also present with urticarial lesions. Patients with coexisting wheals and plaques and who are pregnant are said to have pruritic urticarial papules and plaques of pregnancy (also called polymorphic eruption in pregnancy). A skin biopsy is necessary to confirm premonitory bullous pemphigoid in the elderly when there is no sign of vesicles or bullae.

Bradykinin-mediated disorders, such as angiotensin-converting enzyme (ACE) inhibitor-induced angioedema, hereditary angioedema, as well as angioedema due to acquired C1 inhibitor deficiency, must be taken into consideration in patients presenting with frequent angioedema without wheals. Here, the doctor should closely examine the patient's history, age at symptom onset, duration of attacks, presence of abdominal angioedema episodes, use of concurrent medications (particularly ACE inhibitor intake), lack of response to antihistamines or corticosteroids, and prodromal symptoms. Laboratory evaluation must involve complement C4 levels, C1 inhibitor concentration, and function in every patient with frequent angioedema in whom hereditary angioedema as well as an acquired C1 inhibitor deficiency cannot be ruled out in order to rule out or confirm hereditary angioedema due to C1 inhibitor deficiency.

Classification

According to recent data, there are three subgroups of CSU: autoimmunity type I (CSUaiTI, also known as "autoallergic CSU"), autoimmunity type IIb (CSUaiTIIb), and CSU with an unidentified cause (CSUuc). Type I and type IIb autoimmunity may coexist in some cases. The underlying pathomechanism in the majority of CSU patients is thought to be CSUaiTI, with IgE autoantibodies to autoallergens. IgG or IgM autoantibodies directed against mast cell receptors that are activated cause mast cell activation and degranulation in CSUaiTIIb. Other mechanisms that are currently unknown have significance for the degranulation of skin mast cells in CSUuc. Furthermore, modulating factors like medications, stress, or infections can change how sensitive skin mast cells are to degranulators, which can lead to increased disease activity and/or exacerbation of the disease.

Treatment

A two-pronged strategy has been proposed for the treatment of chronic spontaneous urticaria. First, the underlying cause(s) and/or eliciting trigger(s) must be established and eliminated. Pharmacotherapy is the second, and its goal is to relieve symptoms. Although removing the cause is the ideal course of action, this may not be feasible in many situations. According to current guidelines, a therapeutic approach should be implemented in three steps: (1) taking a second-generation antihistamine once daily; (2) increasing the daily dose of the second-generation antihistamine up to four times; and (3) pursuing off-label therapy with cyclosporine A or montelukast or add-on therapy with omalizumab, which is an approved treatment option for CSU.

Omalizumab works well even in the most difficult, resistant situations. Despite having nearly as good of an efficacy as omalizumab, cyclosporine is regarded as third line because it carries a much higher risk of side effects. Long-term use of corticosteroids is not advised because the side effects increase with dosage and duration and eventually result in greater disability than CSU. However, until other treatments take effect, acute symptoms can be managed with a brief course of steroids.

Outlook

According to one study examining the course of urticaria in the general population, 50% of patients with chronic urticaria had no symptoms after three months, and 80% had no symptoms after twelve months. Still, 11% experienced urticaria after five years.

Epidemiology

It has been discovered by American authors that approximately one in five individuals will at some point in their lives suffer from urticaria of any kind. Similar figures were discovered in a recent Spanish study. Nonetheless, studies conducted in Europe suggest a lower lifetime prevalence, or the prevalence observed throughout one's lifetime up until the investigation, of approximately 8–10%. There is less information on nonacute urticaria. A study conducted forty years ago in Sweden found a point prevalence of about 0.1% in the population overall, and a different study conducted in Spain more recently reported a point prevalence of 0.6% in the population.

See also

References

  1. "Chronic idiopathic urticaria (HPO)". Monarch Initiative. Retrieved December 20, 2023.
  2. ^ "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history". UpToDate. Retrieved December 20, 2023.
  3. ^ "Chronic spontaneous urticaria: Standard management and patient education". UpToDate. Retrieved December 20, 2023.
  4. ^ Termeer, Christian; Staubach, Petra; Kurzen, Hjalmar; Strömer, Klaus; Ostendorf, Rolf; Maurer, Marcus (2015). "Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria". JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 13 (5): 419–428. doi:10.1111/ddg.12633. ISSN 1610-0379. PMID 25918085.
  5. ^ Zuberbier, T.; Aberer, W.; Asero, R.; Abdul Latiff, A. H.; Baker, D.; Ballmer-Weber, B.; Bernstein, J. A.; Bindslev-Jensen, C.; Brzoza, Z.; Buense Bedrikow, R.; Canonica, G. W.; Church, M. K.; Craig, T.; Danilycheva, I. V.; Dressler, C.; Ensina, L. F.; Giménez-Arnau, A.; Godse, K.; Gonçalo, M.; Grattan, C.; Hebert, J.; Hide, M.; Kaplan, A.; Kapp, A.; Katelaris, C. H.; Kocatürk, E.; Kulthanan, K.; Larenas-Linnemann, D.; Leslie, T. A.; Magerl, M.; Mathelier-Fusade, P.; Meshkova, R. Y.; Metz, M.; Nast, A.; Nettis, E.; Oude-Elberink, H.; Rosumeck, S.; Saini, S. S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Staubach, P.; Sussman, G.; Toubi, E.; Vena, G. A.; Vestergaard, C.; Wedi, B.; Werner, R. N.; Zhao, Z.; Maurer, M. (June 25, 2018). "The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria". Allergy. 73 (7). Wiley: 1393–1414. doi:10.1111/all.13397. hdl:10230/35554. ISSN 0105-4538. PMID 29336054.
  6. Maurer, Marcus; Costa, Celia; Gimenez Arnau, AnaMaria; Guillet, Gerard; Labrador-Horrillo, Moises; Lapeere, Hilde; Meshkova, Raisa; Savic, Sinisa; Chapman-Rothe, Nadine (September 3, 2020). "Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study". Clinical & Experimental Allergy. 50 (10). Wiley: 1166–1175. doi:10.1111/cea.13716. hdl:1854/LU-8714221. ISSN 0954-7894. PMID 32735720.
  7. ^ Saini, Sarbjit S.; Kaplan, Allen P. (2018). "Chronic Spontaneous Urticaria: The Devil's Itch". The Journal of Allergy and Clinical Immunology: In Practice. 6 (4). Elsevier BV: 1097–1106. doi:10.1016/j.jaip.2018.04.013. ISSN 2213-2198. PMC 6061968. PMID 30033911.
  8. ^ Saini, Sarbjit S. (2014). "Chronic Spontaneous Urticaria". Immunology and Allergy Clinics of North America. 34 (1). Elsevier BV: 33–52. doi:10.1016/j.iac.2013.09.012. ISSN 0889-8561. PMC 11218737.
  9. Zingale, L. C.; Beltrami, L.; Zanichelli, A.; Maggioni, L.; Pappalardo, E.; Cicardi, B.; Cicardi, M. (October 24, 2006). "Angioedema without urticaria: a large clinical survey". Canadian Medical Association Journal. 175 (9). CMA Joule Inc.: 1065–1070. doi:10.1503/cmaj.060535. ISSN 0820-3946. PMC 1609157. PMID 17060655.
  10. ^ Kozel, Martina M.A.; Bossuyt, Patrick M.M.; Mekkes, Jan R.; Bos, Jan D. (2003). "Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review". Journal of the American Academy of Dermatology. 48 (3). Elsevier BV: 409–416. doi:10.1067/mjd.2003.142. ISSN 0190-9622.
  11. Kolkhir, Pavel; Muñoz, Melba; Asero, Riccardo; Ferrer, Marta; Kocatürk, Emek; Metz, Martin; Xiang, Yi-Kui; Maurer, Marcus (2022). "Autoimmune chronic spontaneous urticaria". Journal of Allergy and Clinical Immunology. 149 (6). Elsevier BV: 1819–1831. doi:10.1016/j.jaci.2022.04.010. ISSN 0091-6749. PMID 35667749.
  12. Confino-Cohen, Ronit; Chodick, Gabriel; Shalev, Varda; Leshno, Moshe; Kimhi, Oded; Goldberg, Arnon (2012). "Chronic urticaria and autoimmunity: Associations found in a large population study". Journal of Allergy and Clinical Immunology. 129 (5). Elsevier BV: 1307–1313. doi:10.1016/j.jaci.2012.01.043. ISSN 0091-6749. PMID 22336078.
  13. Trevisonno, Jordan; Balram, Bhairavi; Netchiporouk, Elena; Ben-Shoshan, Moshe (May 10, 2015). "Physical urticaria: Review on classification, triggers and management with special focus on prevalence including a meta-analysis". Postgraduate Medicine. 127 (6). Informa UK Limited: 565–570. doi:10.1080/00325481.2015.1045817. ISSN 0032-5481. PMID 25959894. S2CID 205452082.
  14. ^ Sánchez, Jorge; Amaya, Emerson; Acevedo, Ana; Celis, Ana; Caraballo, Domingo; Cardona, Ricardo (2017). "Prevalence of Inducible Urticaria in Patients with Chronic Spontaneous Urticaria: Associated Risk Factors". The Journal of Allergy and Clinical Immunology: In Practice. 5 (2). Elsevier BV: 464–470. doi:10.1016/j.jaip.2016.09.029. ISSN 2213-2198. PMID 27838325.
  15. Sánchez, Jorge; Sánchez, Andres; Cardona, Ricardo (June 19, 2018). "Dietary Habits in Patients with Chronic Spontaneous Urticaria: Evaluation of Food as Trigger of Symptoms Exacerbation". Dermatology Research and Practice. 2018. Hindawi Limited: 1–6. doi:10.1155/2018/6703052. ISSN 1687-6105.
  16. ^ Maurer, M.; Weller, K.; Bindslev-Jensen, C.; Giménez-Arnau, A.; Bousquet, P. J.; Bousquet, J.; Canonica, G. W.; Church, M. K.; Godse, K. V.; Grattan, C. E. H.; Greaves, M. W.; Hide, M.; Kalogeromitros, D.; Kaplan, A. P.; Saini, S. S.; Zhu, X. J.; Zuberbier, T. (2011). "Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1: Unmet clinical needs in chronic urticaria". Allergy. 66 (3): 317–330. doi:10.1111/j.1398-9995.2010.02496.x. PMID 21083565.
  17. KAPLAN, A; HORAKOVA, Z; KATZ, S (1978). "Assessment of tissue fluid histamine levels in patients with urticaria". Journal of Allergy and Clinical Immunology. 61 (6). Elsevier BV: 350–354. doi:10.1016/0091-6749(78)90113-6. ISSN 0091-6749. PMID 659726.
  18. SMITH, C; KEPLEY, C; SCHWARTZ, L; LEE, T (1995). "Mast cell number and phenotype in chronic idiopathic urticaria". Journal of Allergy and Clinical Immunology. 96 (3). Elsevier BV: 360–364. doi:10.1016/s0091-6749(95)70055-2. ISSN 0091-6749.
  19. ELIAS, J; BOSS, E; KAPLAN, A (1986). "Studies of the cellular infiltrate of chronic idiopathic urticaria: Prominence of T-lymphocytes, monocytes, and mast cells". Journal of Allergy and Clinical Immunology. 78 (5). Elsevier BV: 914–918. doi:10.1016/0091-6749(86)90240-x. ISSN 0091-6749. PMID 3491100.
  20. Sabroe, Ruth A.; Poon, Eric; Orchard, Guy E.; Lane, David; Francis, David M.; Barr, Robert M.; Black, Martin M.; Black, Anne Kobza; Greaves, Malcolm W. (1999). "Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcϵRI or anti-IgE autoantibodies". Journal of Allergy and Clinical Immunology. 103 (3). Elsevier BV: 484–493. doi:10.1016/s0091-6749(99)70475-6. ISSN 0091-6749. PMID 10069884.
  21. Ying, Sun; Kikuchi, Yoko; Meng, Qiu; Kay, A.Barry; Kaplan, Allen P. (2002). "TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction". Journal of Allergy and Clinical Immunology. 109 (4). Elsevier BV: 694–700. doi:10.1067/mai.2002.123236. ISSN 0091-6749. PMID 11941321.
  22. Kay, A.B.; Clark, P.; Maurer, M.; Ying, S. (April 12, 2015). "Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic') urticaria". British Journal of Dermatology. 172 (5). Oxford University Press (OUP): 1294–1302. doi:10.1111/bjd.13621. ISSN 0007-0963. PMID 25523947. S2CID 207072761.
  23. Kay, A. B.; Ying, S.; Ardelean, E.; Mlynek, A.; Kita, H.; Clark, P.; Maurer, M. (2014). "Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria". Clinical & Experimental Allergy. 44 (8): 1053–1060. doi:10.1111/cea.12348. ISSN 0954-7894. PMID 24902612. S2CID 204981933.
  24. Schmetzer, Oliver; Lakin, Elisa; Topal, Fatih A.; Preusse, Patricia; Freier, Denise; Church, Martin K.; Maurer, Marcus (2018). "IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria". Journal of Allergy and Clinical Immunology. 142 (3). Elsevier BV: 876–882. doi:10.1016/j.jaci.2017.10.035. ISSN 0091-6749.
  25. ^ Kolkhir, Pavel; Church, Martin K.; Weller, Karsten; Metz, Martin; Schmetzer, Oliver; Maurer, Marcus (2017). "Autoimmune chronic spontaneous urticaria: What we know and what we do not know". Journal of Allergy and Clinical Immunology. 139 (6). Elsevier BV: 1772–1781.e1. doi:10.1016/j.jaci.2016.08.050. ISSN 0091-6749. PMID 27777182.
  26. Bossi, F.; Frossi, B.; Radillo, O.; Cugno, M.; Tedeschi, A.; Riboldi, P.; Asero, R.; Tedesco, F.; Pucillo, C. (2011). "Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation: Mast cells and vascular leakage in chronic urticaria". Allergy. 66 (12): 1538–1545. doi:10.1111/j.1398-9995.2011.02704.x. S2CID 5181903.
  27. Cugno, M; Tedeschi, A; Frossi, B; Bossi, F; Marzano, AV; Asero, R (October 19, 2016). "Detection of Low-Molecular-Weight Mast Cell–Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria". Journal of Investigational Allergology and Clinical Immunology. 26 (5). Esmon Publicidad, SA: 310–313. doi:10.18176/jiaci.0051. ISSN 1018-9068. PMID 27763857.
  28. JACQUES, P; LAVOIE, A; BEDARD, P; BRUNET, C; HEBERT, J (1992). "Chronic idiopathic urticaria: Profiles of skin mast cell histamine release during active disease and remission". Journal of Allergy and Clinical Immunology. 89 (6). Elsevier BV: 1139–1143. doi:10.1016/0091-6749(92)90297-f. ISSN 0091-6749. PMID 1376735.
  29. Nettis, E.; Dambra, P.; Loria, M. P.; Cenci, L.; Vena, G. A.; Ferrannini, A.; Tursi, A. (2001). "Mast-cell phenotype in urticaria". Allergy. 56 (9). Wiley: 915. doi:10.1034/j.1398-9995.2001.00296.x. ISSN 0105-4538. S2CID 13293117.
  30. Vonakis, Becky M; Saini, Sarbjit S (2008). "New concepts in chronic urticaria". Current Opinion in Immunology. 20 (6). Elsevier BV: 709–716. doi:10.1016/j.coi.2008.09.005. ISSN 0952-7915. PMC 2610333. PMID 18832031.
  31. Borriello, Francesco; Granata, Francescopaolo; Marone, Gianni (2014). "Basophils and Skin Disorders". Journal of Investigative Dermatology. 134 (5). Elsevier BV: 1202–1210. doi:10.1038/jid.2014.16. ISSN 0022-202X. PMID 24499736.
  32. ^ Metz, Martin; Altrichter, Sabine; Buttgereit, Thomas; Fluhr, Joachim W.; Fok, Jie Shen; Hawro, Tomasz; Jiao, Qingqing; Kolkhir, Pavel; Krause, Karoline; Magerl, Markus; Pyatilova, Polina; Siebenhaar, Frank; Su, Huichun; Terhorst-Molawi, Dorothea; Weller, Karsten; Xiang, Yi-Kui; Maurer, Marcus (2021). "The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why". The Journal of Allergy and Clinical Immunology: In Practice. 9 (6). Elsevier BV: 2274–2283. doi:10.1016/j.jaip.2021.03.049. ISSN 2213-2198. PMID 33857657. S2CID 233257578.
  33. Vestergaard, Christian; Deleuran, Mette (2015). "Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy". Therapeutic Advances in Chronic Disease. 6 (6): 304–313. doi:10.1177/2040622315603951. ISSN 2040-6223. PMC 4622315. PMID 26568807.
  34. Zuberbier, T.; Aberer, W.; Asero, R.; Bindslev-Jensen, C.; Brzoza, Z.; Canonica, G. W.; Church, M. K.; Ensina, L. F.; Giménez-Arnau, A.; Godse, K.; Gonçalo, M.; Grattan, C.; Hebert, J.; Hide, M.; Kaplan, A.; Kapp, A.; Abdul Latiff, A. H.; Mathelier-Fusade, P.; Metz, M.; Nast, A.; Saini, S. S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Simons, F. E. R.; Staubach, P.; Sussman, G.; Toubi, E.; Vena, G. A.; Wedi, B.; Zhu, X. J.; Maurer, M. (April 30, 2014). "The <scp>EAACI</scp>/<scp>GA</scp><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update". Allergy. 69 (7). Wiley: 868–887. doi:10.1111/all.12313. ISSN 0105-4538.
  35. Brodell, Lindsey A.; Beck, Lisa A. (2008). "Differential diagnosis of chronic urticaria". Annals of Allergy, Asthma & Immunology. 100 (3). Elsevier BV: 181–188. doi:10.1016/s1081-1206(10)60438-3. ISSN 1081-1206. PMID 18426134.
  36. ^ Peroni, Anna; Colato, Chiara; Zanoni, Giovanna; Girolomoni, Giampiero (2010). "Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria". Journal of the American Academy of Dermatology. 62 (4). Elsevier BV: 557–570. doi:10.1016/j.jaad.2009.11.687. ISSN 0190-9622. PMID 20227577.
  37. Bonnekoh, H.; Scheffel, J.; Maurer, M.; Krause, K. (November 28, 2017). "Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study". British Journal of Dermatology. 178 (2). Oxford University Press (OUP): 561–562. doi:10.1111/bjd.15705. ISSN 0007-0963. PMID 28580686. S2CID 46821999.
  38. Peroni, Anna; Colato, Chiara; Schena, Donatella; Girolomoni, Giampiero (2010). "Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria". Journal of the American Academy of Dermatology. 62 (4). Elsevier BV: 541–555. doi:10.1016/j.jaad.2009.11.686. ISSN 0190-9622. PMID 20227576.
  39. Wu, Maddalena Alessandra; Perego, Francesca; Zanichelli, Andrea; Cicardi, Marco (2016). "Angioedema Phenotypes: Disease Expression and Classification". Clinical Reviews in Allergy & Immunology. 51 (2): 162–169. doi:10.1007/s12016-016-8541-z. ISSN 1080-0549. PMID 27113957. S2CID 26721778.
  40. de Montjoye, L.; Darrigade, A.S.; Gimenez Arnau, A.; Herman, A.; Dumoutier, L.; Baeck, M. (2021). "Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria". European Annals of Allergy and Clinical Immunology. 53 (2). Edra SpA: 55. doi:10.23822/eurannaci.1764-1489.132. ISSN 1764-1489. PMID 31965967.
  41. Schoepke, Nicole; Asero, Riccardo; Ellrich, André; Ferrer, Marta; Gimenez-Arnau, Ana; E. H. Grattan, Clive; Jakob, Thilo; Konstantinou, George N.; Raap, Ulrike; Skov, Per Stahl; Staubach, Petra; Kromminga, Arno; Zhang, Ke; Bindslev-Jensen, Carsten; Daschner, Alvaro; Kinaciyan, Tamar; Knol, Edward F.; Makris, Michael; Marrouche, Nadine; Schmid-Grendelmeier, Peter; Sussman, Gordon; Toubi, Elias; Church, Martin K.; Maurer, Marcus (2019). "Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study" (PDF). Allergy. 74 (12): 2427–2436. doi:10.1111/all.13949. ISSN 0105-4538. S2CID 195298843.
  42. Asero, R; Marzano, A V; Ferrucci, S; Lorini, M; Carbonelli, V; Cugno, M (March 17, 2020). "Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria". Clinical and Experimental Immunology. 200 (3). Oxford University Press (OUP): 242–249. doi:10.1111/cei.13428. ISSN 0009-9104. PMC 7231996.
  43. Altrichter, Sabine; Zampeli, Vasiliki; Ellrich, André; Zhang, Ke; Church, Martin K; Maurer, Marcus (June 18, 2020). "IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria". Allergy. 75 (12). Wiley: 3208–3215. doi:10.1111/all.14412. ISSN 0105-4538. PMID 32446275.
  44. Kaplan, Allen P.; Joseph, Kusumam; Saini, Sarbjit S. (2015). "How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria". The Journal of Allergy and Clinical Immunology: In Practice. 3 (4). Elsevier BV: 648. doi:10.1016/j.jaip.2015.04.008. ISSN 2213-2198. PMID 26164583.
  45. Kulthanan, Kanokvalai; Chaweekulrat, Pichanee; Komoltri, Chulaluk; Hunnangkul, Saowalak; Tuchinda, Papapit; Chularojanamontri, Leena; Maurer, Marcus (2018). "Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review". The Journal of Allergy and Clinical Immunology: In Practice. 6 (2). Elsevier BV: 586–599. doi:10.1016/j.jaip.2017.07.017. ISSN 2213-2198. PMID 28916431.
  46. ^ Gaig, P; Olona, M; Muñoz Lejarazu, D; Caballero, M T; Domínguez, F J; Echechipia, S; García Abujeta, J L; Gonzalo, M A; Lleonart, R; Martínez Cócera, C; Rodríguez, A; Ferrer, M (2004). "Epidemiology of urticaria in Spain" (PDF). Journal of Investigational Allergology & Clinical Immunology. 14 (3): 214–220. PMID 15552715. Retrieved 22 December 2023.
  47. Sheldon, John M.; Mathews, Kenneth P.; Lovell, Robert G. (1954). "The vexing urticaria problem: Present concepts of etiology and management". Journal of Allergy. 25 (6). Elsevier BV: 525–560. doi:10.1016/s0021-8707(54)90034-9. ISSN 0021-8707. PMID 13211146.
  48. Bakke, P.; Gulsvik, A.; Eide, G. E. (1990). "Hay fever, eczema and urticaria in southwest Norway". Allergy. 45 (7). Wiley: 515–522. doi:10.1111/j.1398-9995.1990.tb00527.x. ISSN 0105-4538. PMID 2252162. S2CID 37734944.
  49. Zuberbier, T.; Balke, M.; Worm, M.; Edenharter, G.; Maurer, M. (April 26, 2010). "Epidemiology of urticaria: a representative cross-sectional population survey". Clinical and Experimental Dermatology. 35 (8). Oxford University Press (OUP): 869–873. doi:10.1111/j.1365-2230.2010.03840.x. ISSN 0307-6938. PMID 20456386. S2CID 41062673.
  50. HELLGREN, LARS (1972). "The Prevalence of Urticaria in the Total Population". Allergy. 27 (3). Wiley: 236–240. doi:10.1111/j.1398-9995.1972.tb01420.x. ISSN 0105-4538. PMID 4678809. S2CID 45351511.

Further reading

External links

ClassificationD
External resources
Urticaria and erythema
Urticaria
(acute/chronic)
Allergic urticaria
Physical urticaria
Other urticaria
Angioedema
Erythema
Erythema multiforme/
drug eruption
Figurate erythema
Other erythema
Category: